Aging
Conditions
Brief summary
SRW Laboratories has formulated the Cel System protocol, a group of three formulas designed to interact with each of the 9 Hallmarks of Aging and combined this with an App that supports positive lifestyle changes, with a view that, if we can positively impact each Hallmark, we can support healthy aging.
Detailed description
This study will measure the impact of the Cel System protocol on the biological clocks of the participants, as well as measure established biomarkers associated with the 9 Hallmarks and note any aesthetic changes you may experience to establish evidence of the effect of the Cel System Protocol over time.
Interventions
DIETARY_SUPPLEMENTSRW Cel System
Dietary supplement
Sponsors
SRW
TruDiagnostic
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women of any ethnicity * 55 years and older * Female subjects must be post-menopausal * Participant must be able to comply with treatment plan and laboratory tests * Participant must be able to read, write, and speak English fluently * Participant must have a smartphone and be able to download and use the App * Participant must have an established primary care provider * Participant must be willing and able to consume study supplements throughout the duration of study period
Exclusion criteria
* History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. * Known immune system issues or immunodeficiency disease * History of viral illness which could be reactivated by immune downregulation * Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) disease * Diagnosis of a transient ischemic attack in the 6 months prior to screening * Participants infected with hepatitis C or HIV * Presence of active infection in previous 4 weeks * Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the Clinical Investigator would render a participant unsuitable to participate in the study * Unable or unwilling to provide required blood sample for testing * Current or previous use of known prescription immunomodulating products (e.g. glucocorticoids, TNF-alpha inhibitors) in the month prior to the start of the trial. * A known history of blood dyscrasias including coagulopathy * Any person deemed by the Investigator as having a low likelihood of complying with study protocol (e.g. evidence of history of non-compliance, history of poor follow-up, multiple or complex scheduling conflicts). * Planned surgical procedure during study period * Participants who are actively engaged in a weight loss program or have started any new medications during the duration of the trial that can potentially interfere with the study, as deemed appropriate by Principal Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biological age | Change in epigenetic age from baseline to 12 months | The primary outcome measure for the study is biological age, measured by DNA methylation, using blood and saliva samples collected from patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory marker IL-6 | Change in inflammatory marker from baseline to 12 months | (IL-6 will also be assessed at 3, 6, and 12 months. |
| C-reactive protein | Change in inflammatory marker from baseline to 12 months | C-reactive protein will also be assessed at 3, 6, and 12 months. |
Countries
United States
Outcome results
None listed